<DOC>
	<DOCNO>NCT00239395</DOCNO>
	<brief_summary>The objective trial ass efficacy safety 7.5 mg meloxicam i.m . daily compare 7.5 mg meloxicam tablet daily p.o . patient osteoarthritis time period 7 day .</brief_summary>
	<brief_title>A Study Compare Meloxicam IM Once Daily Meloxicam Administered Orally Once Daily Patients With Osteoarthritis</brief_title>
	<detailed_description>This randomize ( 1:1 ) , open-label , multi-center , active-control , parallel-group study compare efficacy 7.5 mg meloxicam i.m . daily compare 7.5 mg meloxicam tablet daily p.o . patient osteoarthritis time period 7 day . The primary endpoint : Pain active movement , The secondary endpoint : - Pain rest - Patient status regard change arthritic condition assess patient/investigator - Patient 's assessment arthritic condition - Onset action - Time maximum pain relief - Paracetamol consumption - Withdrawals due inadequate efficacy - Final global assessment efficacy patient/investigator Safety endpoints - Local tolerability assessment injection patient/investigator - Patient 's /Investigator 's assessment overall tolerability - Number , nature severity adverse event - Laboratory investigation - Withdrawals due safety reason Patients eligible trial meet inclusion exclusion criterion give inform consent randomize one two treatment group ( i.e . meloxicam ampoule meloxicam tablet ) . The study period total 8-14 day include screening , randomisation , study drug administration , 7-day follow-up . The relevant assessment perform day randomisation 7-day follow . Study Hypothesis : The null hypothesis interest primary endpoint meloxicam ampoule inferior oral meloxicam . The alternative meloxicam ampoule noninferior oral meloxicam . Comparison ( ) : The primary endpoint study ass pain active movement VAS prior treatment .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<criteria>Male female age 18 year Patients suffer acute painful exacerbation osteoarthritis hip knee . The diagnosis must base clinical sign symptom xray diagnosis plus clinical sign symptom Assessment pain active movement ( patient ) must exceed 40 mm 100 mm visual analogue scale ( VAS ) Symptoms OA require administration NSAIDs Willingness ability provide write informed consent . Known suspected hypersensitivity trial drug excipients , analgesic , antipyretic NSAIDs Any clinical evidence active peptic ulceration last six month Pregnancy breastfeeding ( precaution : attention drawn report NSAIDs report decrease effectivity intrauterine device ) Asthma , nasal polyp , angioneurotic oedema urticaria follow administration aspirin NSAIDs Concomitant treatment anticoagulant ( include heparin ) , lithium Concomitant administration NSAIDs analgesic agent ( except paracetamol 4g/day ) Administration NSAID last 2 day ( 3 day oxicam ) prior first administration trial drug Concomitant treatment oral corticosteroid initiate alter dose previous month Parenteral intraarticular administration corticosteroid previous month Any i.m . injection previous 7 day Any contraindication i.m . injection Clinical evidence know severe cardiac , hepatic , renal , metabolic , haematological disease , mental disturbance , ulcerative colitis Any rheumatological nonrheumatological disease could interfere evaluation efficacy safety Serum creatinine 125 % upper limit normal range ; aspartate transferase ( AST/SGOT ) and/or alkaline transferase ( ALT/SGPT ) 200 % upper limit normal range Platelet count &lt; 100,000/mm3 ; leucocyte count &lt; 3,000/mm3 Synovectomy previous month trial Participation another clinical trial study previous month Previous participation trial Patient unable comply protocol Concomitant therapy specific symptomatic drug OA , chondroitin sulphate , diacerhein , initiate alter dose previous 3 month . Intraarticular administration hyaluronic acid previous month Patients physiotherapy change throughout study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>